Chardan Capital Markets Downgrades NeuBase Therapeutics (NBSE) to Neutral Oct 17, 2022 08:03AM
NeuBase to Participate at Chardan’s 6th Annual Genetic Medicines Conference Sep 22, 2022 04:05PM
NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference Sep 28, 2021 04:05PM
NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Apr 26, 2021 04:01PM
NeuBase Therapeutics (NBSE) Prices $40 Million Public Offering of Common Stock at $5/sh Apr 22, 2021 09:09AM


Apr 22, 2021 09:07AM NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock
Apr 21, 2021 04:01PM NeuBase Therapeutics (NBSE) Announces Proposed Public Offering of Common Stock
Apr 21, 2021 04:01PM NeuBase Therapeutics Announces Proposed Public Offering of Common Stock
Sep 28, 2020 08:00AM NeuBase Therapeutics to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5th
Apr 30, 2020 04:05PM NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Apr 28, 2020 09:45AM NeuBase Therapeutics (NBSE) Prices 5.25M Share Common Offering at $6/Sh
Apr 28, 2020 09:44AM NeuBase Therapeutics Announces Pricing of $31,500,000 Public Offering of Common Stock
Mar 6, 2020 08:12AM Chardan Capital Markets Starts NeuBase Therapeutics (NBSE) at Buy
Sep 26, 2019 09:08AM NeuBase Therapeutics to Present at the Chardan 3rd Annual Genetic Medicines Conference